cyrilzakka/clinical-trials huggingface dataset:
Korean Red Ginseng and Metabolic Syndrome

Five factor consisting of Metabolic syndrome is closely linked by insulin resistance. Until now, several studies have been performed about effects of Korea red ginseng on hypertension, diabetes, and hyperlipidemia, but not metabolic syndrome.

The investigators hypothesize that Korean red ginseng could improve each constituents of metabolic syndrome, arterial stiffness, and inflammatory markers.

The aim of this study is to determine effects of Korean red ginseng on cardiovascular risks in subjects with metabolic syndrome.

The details of study objective are followed by these:

* comparison of blood pressure before and after Korean red ginseng administration
* comparison of metabolic indicator before and after Korean red ginseng administration
* comparison of oxidative stress and inflammatory markers before and after Korean red ginseng administration
* comparison of arterial stiffness before and after Korean red ginseng administration

Eligibility Criteria:
Inclusion Criteria:(three or more of following five factors)

* waist circumference(male: more than 90cm, female: more than 80cm)
* blood pressure(systolic: more than 130mmHg, diastolic: more than 85mmHg)
* fasting plasma glucose: more than 100mg/dL
* fasting triglycerides: more than 150mg/dL
* High-density lipoprotein(HDL)-cholesterol(male: less than 40mg/dL, female: less than 50mg/dL)

Exclusion Criteria: (any one of following factors)

* uncontrolled blood pressure(systolic: more than 160mmHg, diastolic: more than 100mmHg) or subjects taking blood pressure lowering drug
* Type 2 diabetes patients or fasting plasma glucose more than 126mg/dL
* triglyceride more than 400mg/dL, total cholesterol more than 250mg/dL
* subjects taking antilipidemic drug
* past history of coronary heart disease or cerebrovascular disease
Effect of Chrysanthemum Flower Oil and Its Dose-dependency on Hyperuricemia

The aim of this study is to investigate the efficacy and dose-dependency of chrysanthemum flower oil in suppressing serum uric acid.


Eligibility Criteria:
Inclusion Criteria:

* Serum uric acid 6.8-8.9 mg/dL

Exclusion Criteria:

* Taking anti-hyperuricemic drugs
* History of gouty attack
* Taking drugs or functional food that may affect serum uric acid level
* Hypertention, hyperlipidemia, or diabetes millitus
* Participation in any clinical trial within 90 days of the commencement of the trial
* Renal or hepatic dysfunction
* Heart disease
* History of severe disease and/or major surgery
Multimodal Intervention Program for Patients With Metabolic Syndrome

The aim of this study is to identify the psychological, emotional and lifestyle variables that can have an influence on the different components of metabolic syndrome (MetS) and develop a program for change lifestyle in this patients.


Eligibility Criteria:
Inclusion Criteria:

* Between 25 and 65 years age
* Waist circumference \>88 cm for women and \>102 cm for men
* Blood pressure: systolic ≥ 130 mmHg and diastolic ≥ 85 mmHg
* Fasting glucose level ≥ 110mg/dL
* Triglycerides: ≥ 150 mg/dL
* HDL cholesterol ≤40 mg/dL in men and ≤50 mg/DL in women

Exclusion Criteria:

* Osteoarthritis,
* Active inflammatory diseases,
* Severe psychiatric disorders and/or significant cognitive impairment assessed using the Mini-Mental State Examination.
Gentian Violet Treatment for Hidradenitis Suppurativa

This is a survey study being conducted to describe how subjects with Hidradenitis suppurativa (HS) respond to treatment with gentian violet. The study will rely primarily on qualitative survey responses and quantitative changes in skin appearance.

Hidradenitis suppurativa (HS) is a chronic disease of the folliculopilosebaceous unit, often found in intertriginous areas of the body. The pain and impairment of HS leads patients to report a decreased quality of life, even in comparison to other debilitating cutaneous disease states. Pharmalogic management of HS can vary from topical antibiotics or intralesional corticosteroids for mild cases to immunosuppressants and biologic agents in refractory cases. Gentian violet is a topical antiseptic used to treat many cutaneous yeast infections. It also has a role in improving wound healing in sites of active ulceration. It is our hypothesis that gentian violet will help minimize skin trauma in sites of active HS to promote improved wound healing and quality of life.

Eligibility Criteria:
Inclusion Criteria:

* Patients must have active HS, be willing to undergo one application of HS, and agree to follow-up in one month.

Exclusion Criteria:

* Exclusion criteria include children, absent HS lesions at the time of clinic, and cognitive/physical impairments that would make them unable to assess quality of life factors of the survey.
The Effectiveness of Different Exercises in Scoliosis

The aim of this study is to examine the effectiveness of stabilization exercises integrated with Schroth exercises on quality of life, trunk rotation angle, body awareness and sleep quality in young people with scoliosis.

The study will include adolescents who come to Bursa Eforfiz Healthy Living Center for outpatient treatment. Participants will be selected from adolescents between the ages of 10-17. Participants will first read the voluntary consent form and if they agree to participate in the study, they will then be evaluated by a physiotherapist. First, the demographic information of the participants will be questioned and then the evaluation will be done in a single session. Participants will be randomly divided into two groups. These will be the control group and the exercise group. Both groups will perform the determined exercises for 8 weeks in a private clinic with a physiotherapist. Only scales, forms and surveys with Turkish reliability and validity studies will be used in the evaluation methods. The surveys will be uploaded to the digital environment and filled in with the physiotherapist according to the participant's answers. All collected data will be scored by the physiotherapist in accordance with the scoring systems and the obtained data will be evaluated using the SPSS program.

Eligibility Criteria:
Inclusion Criteria:

* Being between 9-17 years of age
* Having a primary curve between 10-40 degrees according to the Cobb method
* Having typical S or C scoliosis
* Being willing to participate in the study
* Having the cognitive capacity to cooperate with the guidance of a physiotherapist

Exclusion Criteria:

* Having a BMI over 30 kg/m2
* Having any neurological, orthopedic, cardiopulmonary disorders other than the diagnosis of scoliosis
* Having had any injuries related to the musculoskeletal system in the last 6 months
* Being unable to fulfill exercise requirements for any reason
Study to Evaluate the Efficacy, Safety and Tolerability of PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Parkinson Disease's Patients

This will be a double-blind, randomised, placebo-controlled parallel-arm phase II proof of concept in subjects with PD treated with a stable dose of levodopa who are experiencing both end-of-dose wearing off and Levodopa-Induced Dyskinesia (LID)


Eligibility Criteria:
Inclusion Criteria:

* Males or females diagnosed after the age of 30 years with idiopathic PD for at least 3 years
* Disease severity of 2 to 4 on the modified Hoehn and Yahr scale when in the OFF state
* Been treated with a stable regimen of levodopa-containing therapy
* Subjects who are on a long-acting formulation of levodopa-containing therapy, including Apodespan PR (or equivalent), must be on a stable dose for at least 6 weeks prior to the first screening visit
* Experienced motor fluctuations with wearing off over a period of at least 3 months prior to randomisation
* Experienced LID over a period of at least 3 months prior to randomisation
* Female subjects will be women of non-childbearing potential
* Subjects must pass a Hauser diary concordance test
* Subjects are able, with or without the help of a caregiver, to understand the purpose and risks of the study and provide signed and dated informed consent and authorisation to use confidential health information in accordance with national and local subject privacy regulations

Exclusion Criteria:

* Subjects with atypical, secondary or drug-induced Parkinsonism
* Subjects with a Mini-Mental State Examination (MMSE) score \<25
* Any known contraindication to the use of levodopa, including a history of malignant melanoma or a history of narrow-angle glaucoma.
* Subjects who have had a clinically significant illness within 4 weeks of first dose, as determined by the Investigator.
* Any advanced, severe or unstable disease (other than PD) that may interfere with the primary and secondary study outcome evaluations
* Subjects who have undergone prior neurosurgical operation for PD or transcranial magnetic stimulation.
* Subjects who are participating in another clinical study (eg, attending follow-up visits) or who have participated in a clinical study involving administration of an investigational drug (new chemical entity) in the past 3 months prior to the baseline visit.
* Female subjects of childbearing potential
* Subjects who are pregnant (as determined by positive serum pregnancy test at screening and/or baseline), breastfeeding or lactating.
* Subjects who, in the opinion of the Investigator, should not participate in this study.
Association Between Pseudoexfoliation Syndrome and Diabetes Mellitus

Pseudoexfoliation syndrome (PEX) is characterized by the deposition of a distinctive fibrillar material in the anterior segment of the eye and was first described in 1917 by Lindberg. It is frequently associated with open angle glaucoma, known as pseudoexfoliation glaucoma, which is one of the most common identifiable forms of secondary open angle glaucoma worldwide. Despite extensive research, the exactchemical nature of the fibrillar material is unknown. It is believed to be secreted multifocally in the iris pigment epithelium, the ciliary epithelium, and the peripheral anterior lens epithelium.


Eligibility Criteria:
Inclusion Criteria:

* Phakic patients presenting to Ophthalmology outpatient clinic Of Assiut University Hospital.

Exclusion Criteria:

* Patients with previous intraocular surgery.
Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients

Hematopoietic stem cell transplantation (HCT)-associated thrombotic microangiopathy (TMA) is an understudied complication of HCT that significantly affects transplant related morbidity and mortality. The investigators hypothesize that early intervention with complement blocker eculizumab will double survival in HCT recipients with high risk TMA, as compared to historical untreated controls. An optimal eculizumab dosing schedule can be determined for this population through eculizumab pharmacokinetic/pharmacodynamic (PK/PD) testing.

This clinical trial is a prospective single arm multi-institution study in children and young adults undergoing allogeneic or autologous hematopoietic stem cell transplantation who will receive early therapy with eculizumab to prevent TMA-associated MODS after transplantation. The purpose of this research study is to examine efficacy of complement blocker eculizumab in HCT recipients with high risk TMA and to determine optimal eculizumab dosing regimen for HCT recipients with TMA using PK/PD studies. All patients will receive therapy based on their weight for 24 weeks. Survival will be assessed at 6 months from TMA diagnosis.

Eligibility Criteria:
Inclusion Criteria:

* Patients of any age undergoing allogeneic or autologous HCT
* Histologic TMA diagnosis OR clinical TMA diagnosis and presenting with high risk disease features including elevated plasma sC5b-9 above laboratory normal value (≥244ng/ml) and proteinuria measured as ≥30mg/dL of protein on random urinalysis x2 or protein/creatinine ratio ≥1mg/mg or patient receiving renal replacement therapy.
* Minimum weight of ≥ 5kg.

Exclusion Criteria:

* Known hypersensitivity to any constituent of the study medication.
* Subjects with unresolved serious Neisseria meningitides infection or progressive severe infection.
* Patients with diagnosis of TTP as defined by ADAMST13 activity test \<10%.
* Patients previously treated with eculizumab or other complement blocker for TMA within the 60 days prior to first dose of study treatment.
ERAS in Posterior Approach of Cervical Spine Operation

Enhanced recovery after surgery (ERAS) strategy has been used in the patient management of different diseases. This study aims to evaluate the effectiveness of ERAS in the perioperative period of posterior approach of cervical spine operation among patients with CSM.

Enhanced recovery after surgery (ERAS) strategy has been used in the patient management of different diseases, but up to now, few effort has been done to evaluate the effectiveness of ERAS in patients perioperative management of cervical spine surgery. As a interdisciplinary cooperation system, either qualitative or quantitative method alone can not completely reflect the function of ERAS. Mixed model research (MMR) is a appropriate method to evaluate a complex system, but it has not been used in ERAS evaluation. This study aims to evaluate the effectiveness of ERAS in the perioperative period of posterior approach of cervical spine operation among patients with CSM using MMR, including the retrospective quantitative part and prospective qualitative part. In the retrospective part, we will collect the data of length of stay, VAS scores, mJOA scores and SF-36 scores to compare the difference between ERAS group and regular group. In the prospective part, we will collect the data from the focus group meetings and personal interviews of patients, to verify that ERAS has the ability to improve the postoperative outcomes, while maintain an equal surgical effect.

Eligibility Criteria:
Inclusion Criteria:

1. Patients should be diagnosed as CSM based on the history, symptoms, Physical signs and radiographic results.
2. Patients did not respond to the 3-month conventional treatment.
3. Patients were performed posterior approach of cervical spine operation.
4. Patients should have complete pre- and post-operative data.

Exclusion Criteria:

1. Patients with severe organic diseases.
2. Patients with previous history of cervical spine surgery.
3. Patients with mental or psychological abnormality.
4. Patients with severe osteoporosis (T value \<-2.5).
Safety and Tolerability of Single and Multiple Doses of VAK694 in Healthy and Atopic Subjects

This study will evaluate the safety and tolerability of single and multiple doses of VAK694 in healthy volunteers and otherwise healthy volunteers with a history of allergies.


Eligibility Criteria:
Inclusion Criteria:

* History of allergic rhinitis (Part 2 only)

Exclusion Criteria:

* Very low or high body weight
* Heavy or recent smoker
* Exposure to human monoclonal antibodies

Other protocol-defined inclusion/exclusion criteria may apply.
"Association Splitting" in Obsessive-Compulsive Disorder (OCD)

Over a period of 3 weeks, association splitting is compared to cognitive remediation (CogPack training) as an add-on intervention to cognitive-behavioral therapy (CBT). Blind to treatment assignment, both groups are assessed before intervention and eight weeks as well as six months later with the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), the Obsessive-Compulsive Inventory (OCI-R) and cognitive tests. OCD severity as measured by the Y-BOCS total score serves as the primary outcome parameter. It is assumed that association splitting will improve OCD severity to a greater extent than cognitive remediation.

Association splitting is a new cognitive technique which aims at reducing obsessive thoughts. It draws upon the so-called "fan effect" of associative priming. Transposing this principle to the treatment of obsessive-compulsive disorder (OCD), we hypothesized that the sprouting of new and the strengthening of existing neutral associations to core OCD cognitions will reduce their fear-evoking properties by depriving the chain of OCD-related cognitions of associative strength. Patients with OCD are randomly allocated to either associations splitting (AS) or cognitive remediation (CogPack training). Blind to treatment assignment, both groups are assessed before intervention and eight weeks as well as six months later with the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), the Obsessive-Compulsive Inventory (OCI-R) and cognitive tests. OCD severity derived from the Y-BOCS and the OCI-R serves as the main outcome parameters. We also explore if AS changes the OCD-related semantic networks with cognitive tasks. It is assumed that association splitting will improve OCD severity to a greater extent than CogPack training.

Eligibility Criteria:
Inclusion Criteria:

* Obsessive-Compulsive Disorder (OCD) with an Y-BOCS obsession subscore ≥ 8

Exclusion Criteria:

* intellectual disability (IQ \< 70); unable to provide informed consent; severe neurological illness, psychotic symptoms or substance dependence.
The Effects of Muscle Energy Techniques on Pain and Quality of Life in Young Females With Primary Dysmenorrhea

This study will be a quasi experimental study in which females aged 18 - 30 years with primary dysmenorrhea will be recruited in single group. They will be given a total of 3 sessions of treatment during a period of one menstrual cycle (One Week). Before and after the introduction of intervention pain and quality of life of participants will be assessed.

Primary Dysmenorrhea is one of the most prevalent gynecological conditions which impacts the quality of life of young females.Primary dysmenorrhea is defined as cramping like pain during menstruation cycle without the presence of any pelvic pathology it is associated with symptoms like headache,vomitting and irritability.The aim of our study is to determine the effects of muscle energy technique in young females with primary dysmenorrhea in terms of pain and quality of life.This study will be a Quasi Experimental study.It will be conducted at Foundation university college of physical therapy.Paticipants will complete WALIDD scale,NPRS and WHOQOL at baseline and then after intervention.All participants will receive post isometric relaxation of global muscles of core commonly involved in primary dysmenorrhea(Gluteus Maximus,Illiopsoas and Piriformis).Post isometric relaxation technique will be applied to all the participants with participants using 20% of their maximum voluntary contractio with held time of 6-10 seconds followed by 15 to 30 seconds stretch,rest time of 5 seconds between each repetitions and 3-5 repetions.There will be a total of 3 sessiond of treatment(1st on second day of menstruation,2nd on fourth day of menstruatio and 3rd on seventh day of menstruation)during a period of one week (one menstraul cycle).

Eligibility Criteria:
Inclusion Criteria:

* Female aged 18 - 30
* Primary Dysmenorrhea
* Unmarried

Exclusion Criteria:

* Not on any contraceptive medicine for treatment of pelvic pathology
* Secondary Dysmenorrhea and other issues such as endometriosis, Pelvic inflammatory disease, Ovarian cyst
Sunlight Exposure and Vitamin D Status of Children of South Asian Ethnicity Living in the UK

The purpose of this study is to examine the amount of sunlight exposure and vitamin D status of adolescent schoolchildren of South Asian ethnicity in each season throughout the year.


Eligibility Criteria:
Inclusion Criteria:

* Healthy schoolchildren aged 12-15 years
* Sun-reactive skin type V (naturally brown skin)
* South Asian ethnicity
* Male or female

Exclusion Criteria:

* History of photosensitivity disorder
* Non-ambulant
The Safety and Efficacy of Etanercept (Enbrel®) for the Treatment of Discoid Lupus Erythematosus

A 20 week study to assess the safety and efficacy of etanercept(Enbrel®)for the treatment of Discoid Lupus Erythematosus


Eligibility Criteria:
Inclusion Criteria:

* Subjects with discoid lupus erythematosus .Subjects require to have confirmation of diagnosis by a skin biopsy .This can be undertaken at the screening visit if no previous biopsy confirmation available.

And;

* Having failed steroids (topical, intralesional, systemic) and are candidates for antimalarial therapy
* Negative ANA

Have no history of latent or active TB prior to screening.

Exclusion Criteria:

* Subjects allergic to sunscreens
* Prior treatment with anti-TNF therapies
* Subjects who do not have a previous skin biopsy result confirming a DLE diagnosis and who are unwilling to undergo this procedure at screening.
* Subjects currently receiving systemic steroid therapy (or have received in the last 3 months)
* Known hypersensitivity to Enbrel® (etanercept) or any of its components or known to have antibodies to etanercept.
* Prior or concurrent use of cyclophosphamide therapy
* Concurrent sulfasalazine therapy.
* Known HIV-positive status or known history of any other immuno-suppressing disease.
* Any mycobacterial disease or high risk factors for tuberculosis (TB), such as family member with TB, positive purified protein derivative (PPD) or taking anti-tuberculosis medication
* Active or chronic infection within 4 weeks before screening visit, or between the screening and baseline visits.
* Severe comorbidities (diabetes mellitus requiring insulin; CHF of any severity; or myocardial infarction, cerebrovascular accident or transient ischemic attack within 6 months of screening visit; unstable angina pectoris; uncontrolled hypertension (sitting systolic BP \<80 mm Hg or \> 160 or diastolic BP \> 100 mm Hg); oxygen-dependent severe pulmonary disease; history of cancer within 5 years \[other than resected cutaneous basal or squamous cell carcinoma of the skin or in situ cervical cancer\])
* Systemic lupus erythematosus, history of multiple sclerosis, transverse myelitis, optic neuritis or seizure disorder.
Effect of Practicing Yoga and Meditation on Cortisol Hormone, Immunoglobulin a and Metabolic Parameter Among Medical Students

This clinical trial aims to develop and test a yoga intervention to improve cortisol hormone rhythm, immunoglobulin A, and metabolic markers among medical students. The development of the yoga protocol, "GSY Goodbye Stress with Yoga Proto-col," was a collaborative effort involving a certified yoga trainer, medical researcher, and experienced yogis from India. GSY yoga intervention, which includes yoga asanas poses, breathing techniques, and guided meditation, may reduce stress levels, improve immunity, and enhance other metabolic parameters in medical students.

PRIMARY OBJECTIVE:

1. To examine the effectiveness of yoga intervention as a stress reduction technique and measure its effects on the level of cortisol, immunoglobulin A (IgA), and metabolic parameters.
2. To Compare the outcomes of a yoga intervention group to a non-yoga intervention group to determine whether practicing yoga can reduce the negative impacts of elevated cortisol on the physiological parameters.

SECONDARY OBJECTIVES:

1. To determine the correlation between the psychophysiological stress and cortisol hormone in students.
2. To investigate the effect of yoga intervention on student mental health and well-being.

OUTLINE:

Participants receive yoga intervention from a certified yoga trainer once a week for 10 weeks.

Eligibility Criteria:
Inclusion Criteria:

The inclusion criteria for the study required participants to be currently enrolled in the Medicine Faculty of the University of Pecs

Exclusion Criteria:

Students with illnesses (such as recent injuries, chronic pain, or significant arthritis) that would make it unsafe for them to take part in a yoga intervention will be excluded from the study.